UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Gilead Sciences on Monthly HCV Market Model - Gilead Sciences (NASDAQ:GILD)

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

In a report published Tuesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD), and raised the price target from $48.00 to $69.00.In the report, Karnauskas noted, “We built a monthly HCV market model and analyzed prior treatment trends to derive our estimates for 14,15-16, and 17+ as GILD plans to provide some color YE on these markets. Our conclusion is that SOF can sell WW $3.7B, $8.4B, $12.4B in 14, 15, and peak respectively. We analyzed the co's new HIV drug TAF and now include its impact in our model. Maintain Buy.”Gilead Sciences closed on Monday at $50.67.

27% profits every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!